This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.
Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View
by Zacks Equity Research
Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.
Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store?
by Zacks Equity Research
Horzion Pharma's (HZNP) primary care business is under pressure and we expect earnings to disappoint in the third quarter.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.
Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales
by Zacks Equity Research
Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.
Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.
What to Expect from Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx (KERX) will focus on the label expansion of its only approved drug, Auryxia, during the third-quarter 2017 earnings call.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Intrexon (XON) will remain focused on its performance along with other developmental updates in the third quarter of 2017.
Will Endocyte (ECYT) Disappoint This Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.
Is a Beat in the Cards for Mylan (MYL) This Earnings Season?
by Zacks Equity Research
Mylan N.V. (MYL) is likely to beat results when it reports third-quarter results next week driven by newly launched generics.
What's in the Cards for Prothena (PRTA) in Q3 Earnings?
by Zacks Equity Research
Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.
What's in Store for Juno Therapeutics (JUNO) in Q3 Earnings?
by Zacks Equity Research
Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q3.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.
Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
by Zacks Equity Research
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the company's third-quarter results.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) top line is expected to be driven by newly launched Apoquel, Simparica and Cytopoint. The approvals of Clavamox and Nexvet are expected to boost sales further.
Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?
by Zacks Equity Research
Teva's (TEVA) generic segment may continue to see weakness due to significant competitive and pricing pressure in the U.S. generics industry, which will continue to hurt the top line.
What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?
by Zacks Equity Research
Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.
What's in the Offing for Intercept (ICPT) in Q3 Earnings?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.
Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View
by Zacks Equity Research
Alkermes' (ALKS) earnings beat estimates but sales lagged the same in the third quarter of 2017.
Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised
by Zacks Equity Research
Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.
Is a Beat in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to report third-quarter 2017 on Oct 26.
Agenus (AGEN) Remains Focused on Drug Development Programs
by Zacks Equity Research
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
Why Is Agenus (AGEN) Down 11.8% Since the Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.